We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $127B
1-Year Est. Return 46.06%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$1.42B
Cap. Flow %
5.88%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,117
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.36%
2 Miscellaneous 19.43%
3 Financials 16.99%
4 Technology 14.07%
5 Consumer Discretionary 11.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SKX
26
DELISTED
Skechers
SKX
$103M 0.43%
2,455,845
+735,350
+43% +$36.4M
TWST icon
27
Twist Bioscience
TWST
$8.43B
$101M 0.42%
948,490
-63,363
-6% -$7.26M
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$134B
$101M 0.42%
556,678
+5,719
+1% +$1.12M
DVAX
29
DELISTED
Dynavax Technologies
DVAX
$98.3M 0.41%
+5,116,856
New +$68M
GDX icon
30
CALL
VanEck Gold Miners ETF
GDX
$29.9B
$96.9M 0.4%
3,288,400
+511,400
+18% +$16.7M
AMD icon
31
Advanced Micro Devices
AMD
$826B
$94.1M 0.39%
914,781
+800,612
+701% +$81.8M
NSTG
32
DELISTED
NanoString Technologies, Inc.
NSTG
$92.3M 0.38%
1,922,002
+30,622
+2% +$1.76M
AMD icon
33
PUT
Advanced Micro Devices
AMD
$826B
$88.6M 0.37%
860,900
+533,700
+163% +$54.6M
GOOGL icon
34
Alphabet (Google) Class A
GOOGL
$4.14T
$86.2M 0.36%
644,700
+44,460
+7% +$6.05M
ITCI
35
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$85.6M 0.36%
2,295,634
-475,670
-17% -$16.5M
INSP icon
36
Inspire Medical Systems
INSP
$1.8B
$85.3M 0.35%
366,149
-70,080
-16% -$14.6M
GIS icon
37
General Mills
GIS
$20.2B
$84M 0.35%
1,403,426
+1,031,272
+277% +$60.9M
VMW
38
DELISTED
VMware, Inc
VMW
$83.6M 0.35%
562,305
+167,403
+42% +$25.4M
TRU icon
39
TransUnion
TRU
$14.9B
$83M 0.34%
738,751
-13,628
-2% -$1.6M
XPEV icon
40
XPeng
XPEV
$10.5B
$80.7M 0.34%
2,269,780
+1,343,325
+145% +$53.3M
EMB icon
41
CALL
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$14.6B
$78.8M 0.33%
715,900
+559,600
+358% +$62.9M
DAVA icon
42
Endava
DAVA
$152M
$78.5M 0.33%
578,204
-67,167
-10% -$8.67M
QTRX icon
43
Quanterix
QTRX
$129M
$77.5M 0.32%
1,556,000
+141,431
+10% +$7.29M
SPGI icon
44
S&P Global
SPGI
$127B
$75.1M 0.31%
176,793
+101,370
+134% +$43.9M
XOP icon
45
PUT
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$4.19B
$74.4M 0.31%
769,100
+413,100
+116% +$35.2M
SE icon
46
Sea Limited
SE
$69.4B
$73.3M 0.3%
230,070
+214,291
+1,358% +$65.8M
MRVI icon
47
Maravai LifeSciences
MRVI
$1.07B
$73M 0.3%
1,488,016
+1,414,052
+1,912% +$69M
XOP icon
48
CALL
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$4.19B
$72.9M 0.3%
753,700
+663,000
+731% +$56.4M
NFLX icon
49
Netflix
NFLX
$320B
$72.8M 0.3%
1,192,710
-1,255,850
-51% -$69.1M
JNJ icon
50
Johnson & Johnson
JNJ
$649B
$71.8M 0.3%
444,876
+35,052
+9% +$5.98M

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $1.42B of net new capital in Q3 2021, opening 1,117 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,117 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.